

PHARMESIS INTERNATIONAL LTD.
(Incorporated in the Republic of Singapore)
(Company Registration No.: 200309641E)
(the “**Company**”)

Minutes of the 22nd Annual General Meeting (“**AGM**”) of the Company held at 5 Kallang Sector, #03-02, Singapore 349279 on Wednesday, 29 April 2026 at 11.00 a.m.

Present : Mr. Chew Heng Ching - Non-Independent Non-Executive Chairman
Mr. Wu Xuedan* - Executive Director and Chief Executive Officer (“**CEO**”)
Mr. Seow Yong Teng - Independent Non-Executive Director
Ms. Li Li Jie* - Independent Non-Executive Director

Invitees/ : As per attendance lists
Members/

Proxies (Due to the restriction on the use of personal data pursuant to the provision of the Personal Data Protection Act 2012, the names of the invitees, members and proxies present at the meeting will not be published in this minutes.)

** participated via electronic means*

CHAIRMAN

On behalf of the Board of Directors, Mr. Chew Heng Ching, the Chairman of the Company (the “**Chairman**”) welcomed all attendees to the AGM.

The Chairman introduced his fellow Board members, the Company’s Financial Controller, representatives from Messrs. Ernst & Young LLP and Tricor Singapore Pte. Ltd. who were in attendance at the meeting.

QUORUM

After ascertaining a quorum being present, the Chairman called the meeting to order at 11.00 a.m.

NOTICE

The notice convening the meeting dated 14 April 2026 was taken as read.

VOTING PROCEDURES

The Chairman informed the meeting that pursuant to Rule 730A(2) of the Listing Manual of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”), all the proposed resolutions put forth at the meeting would be decided by way of poll.

PHARMESIS INTERNATIONAL LTD

Minutes of the 22nd Annual General Meeting held on 29 April 2026

The Chairman informed that all the proposed resolutions would be voted by poll pursuant to Article 61 of the Company's Constitution. Poll voting process would take place after all the proposed resolutions had been duly tabled and proposed.

The Meeting was further informed of the appointment of In.Corp Corporate Services Pte. Ltd. as Polling Agent; and Aventus Corporate Services Pte. Ltd. as Scrutineer for the polling procedures.

Poll formalities would be explained by the Scrutineer after all resolutions have been duly tabled and proposed.

WRITTEN QUESTIONS AHEAD OF MEETING

The Chairman informed that the Company did not receive any written questions from members ahead of the meeting.

The Chairman then invited the members to raise questions on the proposed resolutions.

There was no question raised on the proposed resolutions and the Chairman then proceeded to put the following proposed resolutions to vote.

ORDINARY BUSINESS

RESOLUTION 1 – DIRECTORS' STATEMENT AND AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025 ("FY2025") AND THE AUDITORS' REPORT

The first item on the Agenda was to receive and adopt the Directors' Statement and Audited Financial Statements of the Company for FY2025 and the Auditors' Report thereon. The Directors' Statement and Audited Financial Statements and the Auditors' Report were set out on pages 40 to 100 of the Annual Report for FY2025.

The Chairman proposed the following motion be put to vote:

"That the Directors' Statement and Audited Financial Statements for the financial year ended 31 December 2025 and the Auditors' Report thereon be received and adopted."

RESOLUTION 2 - RE-ELECTION OF MR. WU XUEDAN AS A DIRECTOR

Resolution 2 was to re-elect Mr. Wu Xuedan ("**Mr. Wu**") as a Director of the Company. Mr. Wu was retiring pursuant to Article 91 of the Constitution of the Company, and being eligible, had signified his consent to continue in office.

The Chairman informed that, upon re-election of Mr. Wu as a Director of the Company, he will remain as Executive Director and Chief Executive Officer of the Company.

The Chairman proposed the following motion be put to vote:

"That Mr. Wu Xuedan be re-elected as a Director of the Company."

PHARMESIS INTERNATIONAL LTD

Minutes of the 22nd Annual General Meeting held on 29 April 2026

RESOLUTION 3 – RE-ELECTION OF MR. SEOW YONG TENG AS A DIRECTOR

Resolution 3 was to re-elect Mr. Seow Yong Teng (“**Mr. Seow**”) as a Director of the Company. Mr. Seow was retiring pursuant to Article 91 of the Constitution of the Company, and he, being eligible for re-election, had signified his consent to continue in office.

The Chairman informed that, upon re-election of Mr. Seow as a Director of the Company, he will remain as the Independent Non-Executive Director of the Company and remain as Chairman of the Audit Committee, Nominating Committee and Remuneration Committee.

The Chairman proposed the following motion be put to vote:

“That Mr. Seow be re-elected as a Director of the Company.”

RESOLUTION 4 – PAYMENT OF DIRECTORS' FEES

The Chairman informed that Resolution 4 was to approve the payment of Directors' fees for financial year ending 31 December 2026 (“FY2026”).

The Chairman proposed the following motion be put to vote:

“That the Directors' Fees of S\$92,000 for the financial year ending 31 December 2026 be approved.”

RESOLUTION 5 - RE-APPOINTMENT OF AUDITORS

The last item of the ordinary business was to re-appoint Messrs Ernst & Young LLP as auditors of the Company for FY2026 and to authorise the Directors to fix their remuneration.

Messrs Ernst & Young LLP had expressed their willingness to continue in office.

The Chairman proposed the following motion be put to vote:

“That Messrs Ernst & Young LLP be re-appointed as Auditors of the Company to hold office until the conclusion of the next annual general meeting and that the Directors be authorised to fix their remuneration.”

ANY OTHER ORDINARY BUSINESS

The Chairman proceeded to Agenda 6 and informed the meeting that there was no notice of other ordinary business to be transacted. As such, the Chairman proceeded to consider the following special business.

SPECIAL BUSINESS

RESOLUTION 6 - AUTHORITY TO ALLOT AND ISSUE SHARES

The Chairman informed the meeting that Resolution 6 was on authority to allot and issue new shares in the capital of the Company pursuant to Section 161 of the Companies Act 1967 and Rule 806(2) of the Listing Manual of the SGX-ST.

PHARMESIS INTERNATIONAL LTD

Minutes of the 22nd Annual General Meeting held on 29 April 2026

The Chairman proposed the following motion be put to vote:

“That, pursuant to Section 161 of the Companies Act 1967 (the “Act”) and Rule 806(2) of the Listing Manual of the Singapore Exchange Securities Trading Limited (“SGX-ST”), authority be and is hereby given to the Directors of the Company to:-

- (a) (i) allot and issue shares in the capital of the Company (“shares”) whether by way of rights, bonus or otherwise; and/or**
- (ii) make or grant offers, agreements or options (collectively, “Instruments”) that might or would require shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) warrants, debentures or other instruments convertible into shares,**

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors may in their absolute discretion deem fit; and

- (b) (notwithstanding the authority conferred by this Resolution may have ceased to be in force) issue shares in pursuance of any Instrument made or granted by the Directors while this Resolution was in force,**

provided that:

- (1) the aggregate number of shares to be issued pursuant to this Resolution (including shares to be issued in pursuance of Instruments made or granted pursuant to this Resolution) does not exceed fifty per cent (50%) of the Company’s total number of issued shares (excluding treasury shares and subsidiary holdings) (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of shares to be issued other than on a *pro rata* basis to existing shareholders of the Company (including shares to be issued in pursuance of Instruments made or granted pursuant to this Resolution) does not exceed twenty per cent (20%) of the Company’s total number of issued shares (excluding treasury shares and subsidiary holdings) (as calculated in accordance with sub-paragraph (2) below);**
- (2) (subject to such manner of calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of shares (including shares to be issued in pursuance of Instruments made or granted pursuant to this Resolution) that may be issued under sub-paragraph (1) above, the total number of issued shares (excluding treasury shares and subsidiary holdings) is based on the Company’s total number of issued shares (excluding treasury shares and subsidiary holdings) at the time this Resolution is passed, after adjusting for:**
 - (i) new shares arising from the conversion or exercise of any convertible securities;**
 - (ii) new shares arising from exercise of share options or vesting of share awards, provided that share options or awards were granted in compliance with the Listing Manual of the SGX-ST; and**
 - (iii) any subsequent bonus issue, consolidation or subdivision of shares,**

provided further that adjustments in accordance with (2)(i) and (ii) above are only to be made in respect of new shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of passing of this Resolution.

PHARMESIS INTERNATIONAL LTD

Minutes of the 22nd Annual General Meeting held on 29 April 2026

- (3) in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Listing Manual of the SGX-ST for the time being in force (unless such compliance has been waived by the SGX-ST), all applicable requirements under the Act and the Constitution of the Company for the time being; and
- (4) (unless revoked or varied by the Company in general meeting) the authority conferred by this Resolution shall continue in force until the conclusion of the next Annual General Meeting of the Company or the date by which the next Annual General Meeting of the Company is required by law to be held, whichever is the earlier.”

POLL VOTING

The Chairman proceeded with the formalities of conducting a poll. The Chairman invited the Scrutineer from Aventus Corporate Services Pte. Ltd. to explain the voting procedures.

After the Scrutineer explained the voting procedures, the meeting paused at 11.06 a.m. for vote tabulation and verification.

The meeting resumed at 11.08 a.m. to announce the results of the poll.

DECLARATION OF VERIFIED POLL RESULTS

Based on the verified poll results, the Chairman of the meeting declared that all the resolutions proposed tabled at the AGM were duly carried:

Resolutions number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
ORDINARY BUSINESS					
Resolution 1 Directors Statement and Audited Financial Statements for the financial year ended 31 December 2025 and the Auditors' Report	12,783,000	12,783,000	100	0	0
Resolution 2 Re-election of Mr. Wu Xuedan as a Director of the Company	12,783,000	12,783,000	100	0	0
Resolution 3 Re-election of Mr. Seow Yong Teng as a Director of the Company	12,783,000	12,783,000	100	0	0

PHARMESIS INTERNATIONAL LTD*Minutes of the 22nd Annual General Meeting held on 29 April 2026*

Resolution 4 Directors' fees of S\$92,000 for the financial year ending 31 December 2026, payable quarterly in arrears	12,783,000	12,783,000	100	0	0
Resolution 5 Re-appointment of Messrs Ernst & Young LLP as Auditors of the Company and authorise the Directors to fix their remuneration	12,783,000	12,783,000	100	0	0
SPECIAL BUSINESS					
Resolution 6 Authority to allot and issue shares	12,783,000	12,783,000	100	0	0

CLOSE OF MEETING

The Board thanked Members for their attendance and declared the meeting closed at 11.09 a.m.

CONFIRMED AS TRUE AND CORRECT RECORD OF PROCEEDINGS

CHEW HENG CHING
CHAIRMAN OF THE MEETING